Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 3/20 | 0.53 |
| ▸ | CTSS | P25774 | 7/20 | 0.52 |
| ▸ | CTSK | P43235 | 6/20 | 0.52 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | PPARA | Q07869 | 1/20 | 0.51 |
| ▸ | CTSB | P07858 | 2/20 | 0.44 |
| ▸ | BCL2 | P10415 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.43 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.42 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21528662 | 0.85 | KIFC1 (0.46) | ACEPPARGPPARANOS3NOS1 | |
| SCHEMBL21528660 | 0.85 | KIFC1 (0.46) | ACEPPARGPPARANOS3NOS1 | |
| SCHEMBL975347 | 0.82 | CTSS (0.63) | ACECTSSCTSKCTSBCTSL | |
| SCHEMBL29666452 | 0.82 | CTSS (0.57) | CTSSCTSKPPARGPPARACTSB | |
| SCHEMBL3556235 | 0.82 | PPARA (0.67) | ACECTSSCTSKPPARGPPARA | |
| SCHEMBL8112750 | 0.82 | PPARG (0.60) | ACECTSSCTSKPPARGPPARA | |
| SCHEMBL441305 | 0.82 | PPARA (0.67) | ACECTSSCTSKPPARGPPARA | |
| SCHEMBL1519728 | 0.82 | PPARA (0.67) | ACECTSSCTSKPPARGPPARA | |
| SCHEMBL21549384 | 0.81 | PPARG (0.49) | ACECTSSCTSKPPARGPPARA | |
| SCHEMBL1741898 | 0.81 | NOS3 (0.57) | ACECTSSCTSKPPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11384060-B2 | Amide compounds and use thereof | ALPHALA CO., LTD. (TW) | 2022-07-12 | — | — | US | disclosed |
| US-11384060-B2 | Amide compounds and use thereof | ALPHALA CO., LTD. (TW) | 2022-07-12 | — | — | US | disclosed |
| US-20190337915-A1 | AMIDE COMPOUNDS AND USE THEREOF | ALPHALA CO., LTD. (TW) | 2019-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190337915-A1 | AMIDE COMPOUNDS AND USE THEREOF | GLP1R, IAPP, GPR119 | ACE 645/4885CTSS 3664/4885CTSK 3370/4885 |
| US-11384060-B2 | Amide compounds and use thereof | GLP1R, IAPP, GPR119 | ACE 645/4885CTSS 3664/4885CTSK 3370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.